Leen C L, Yap P L, Neill G, McClelland D B, Westwood A
Vox Sang. 1986;50(1):26-32. doi: 10.1111/j.1423-0410.1986.tb04841.x.
The intravenous immunoglobulin (IV. IgG) preparation used in this study is manufactured by the Scottish National Blood Transfusion Service (SNBTS) by the pH 4/mild pepsin method. Recent reports suggest that non-A, non-B hepatitis may be transmitted by certain intravenous immunoglobulin preparations. Serum ALT levels were therefore measured prospectively in 16 patients with primary hypogammaglobulinaemia who received an intravenous immunoglobulin replacement therapy (SNBTS IV IgG) over a period ranging from 6 to 25 months. Retrospective analysis of serum ALT levels was also carried out in 8 patients with primary hypogammaglobulinaemia who received fresh frozen plasma (FFP) for periods ranging from 8 months to 13 years. There was no evidence of non-A, non-B hepatitis transmission by either SNBTS IV IgG or by FFP in all the patients studied.
本研究中使用的静脉注射免疫球蛋白（IV. IgG）制剂由苏格兰国家输血服务中心（SNBTS）采用pH 4/温和胃蛋白酶法生产。最近的报告表明，某些静脉注射免疫球蛋白制剂可能传播非甲非乙型肝炎。因此，对16例原发性低丙种球蛋白血症患者进行了前瞻性血清ALT水平检测，这些患者接受了为期6至25个月的静脉注射免疫球蛋白替代治疗（SNBTS IV IgG）。还对8例原发性低丙种球蛋白血症患者进行了血清ALT水平的回顾性分析，这些患者接受新鲜冷冻血浆（FFP）治疗的时间为8个月至13年。在所有研究患者中，均未发现SNBTS IV IgG或FFP传播非甲非乙型肝炎的证据。
